Please enable JavaScript to continue using this application.

Compare $ARDX vs $GLUE | Chartloom

Compare

$ARDX vs $GLUE

Ardelyx Inc · Monte Rosa Therapeutics Inc

ARDX

Ardelyx Inc

GLUE

Monte Rosa Therapeutics Inc

Compare $ARDX vs $GLUE

Comparing Ardelyx Inc and Monte Rosa Therapeutics Inc

ARDXArdelyx Inc

GLUEMonte Rosa Therapeutics Inc

ARDXArdelyx Inc

Market cap

$810M

P/E (TTM)

—

Forward P/E (NTM)

688.58x

Forward P/S (NTM)

1.51x

Rev growth (TTM)

16.8%

YTD performance

-46.7%

52W performance

-35.2%

FCF yield

-2.2%

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ARDX

GLUE

Detailed metrics comparison

ARDX

Ardelyx Inc

GLUE

Monte Rosa Therapeutics Inc

Market Cap

ARDX$810M

GLUE$870M

Enterprise Value

ARDX$965M

GLUE$780M

Price

ARDX$3.28

GLUE$10.30

P/E Ratio

ARDXN/A

GLUEN/A

P/S Ratio

ARDX1.80x

GLUE30.29x

EV/Sales

ARDX2.14x

GLUE27.15x

EV/EBITDA

ARDX454.80x

GLUE47.84x

P/B Ratio

ARDX5.59x

GLUE1.84x

P/FCF Ratio

ARDXN/A

GLUEN/A

EV/FCF

ARDX-53.85x

GLUE-24.32x

PEG Ratio

ARDXN/A

GLUEN/A

Forward P/E (NTM)

ARDX688.58x

GLUEN/A

Forward P/S (NTM)

ARDX1.51x

GLUE21.85x

Revenue (TTM)

ARDX$451M

GLUE$29M

Revenue Growth (YoY)

ARDX16.8%

GLUE-83.9%

Forward Rev Growth

ARDX27.5%

GLUE-58.1%

Gross Margin (TTM)

ARDX94.4%

GLUE0.0%

Operating Margin (TTM)

ARDX0.0%

GLUE0.0%

EBITDA Margin (TTM)

ARDX-7.1%

GLUE-604.8%

Net Margin (TTM)

ARDX-12.4%

GLUE-560.9%

FCF Margin (TTM)

ARDX-4.0%

GLUE-111.7%

Net Income (TTM)

ARDX$-56M

GLUE$-161M

FCF (TTM)

ARDX$-18M

GLUE$-32M

EPS (TTM)

ARDX-$0.22

GLUE-$1.59

ROE (TTM)

ARDX-3600.0%

GLUE-4331.0%

ROA (TTM)

ARDX-1077.0%

GLUE-2759.0%

ROIC (TTM)

ARDX-1506.0%

GLUE-4331.0%

Cash

ARDX$97M

GLUE$90M

Debt

ARDX$252M

GLUE$0

Net Cash/Debt

ARDX$-155M

GLUE$90M

Current Ratio (TTM)

ARDX3.34x

GLUE10.58x

Quick Ratio (TTM)

ARDX2.89x

GLUE10.49x

Debt/Equity (TTM)

ARDX1.69x

GLUE0.00x

Debt/Assets (TTM)

ARDX0.0%

GLUE0.0%

Interest Coverage (TTM)

ARDXN/A

GLUEN/A

Net Debt/EBITDA (TTM)

ARDX0.00x

GLUE0.00x

Beta

ARDX0.72

GLUE1.34

52W Performance

ARDX-35.2%

GLUE33.6%

YTD Performance

ARDX-46.7%

GLUE-32.7%

% from 52W High

ARDX-61.0%

GLUE-60.0%

% from 52W Low

ARDX3.1%

GLUE34.7%

Asset Turnover (TTM)

ARDX0.87x

GLUE0.05x

FCF Yield (TTM)

ARDX-2.2%

GLUE-3.7%

Earnings Yield (TTM)

ARDX-6.9%

GLUE-18.5%

Dividend Yield (TTM)

ARDXN/A

GLUEN/A

Rule of 40

ARDX12.8

GLUE-195.5

EV/GP/RG

ARDX0.10

GLUEN/A

Ticker research

View ARDX research View GLUE research

Metric	ARDX Ardelyx Inc	GLUE Monte Rosa Therapeutics Inc
Market & Valuation
Market Cap	$810M	$870M
Enterprise Value	$965M	$780M
Price	$3.28	$10.30
P/E Ratio	N/A	N/A
P/S Ratio	1.80x	30.29x
EV/Sales	2.14x	27.15x
EV/EBITDA	454.80x	47.84x
P/B Ratio	5.59x	1.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-53.85x	-24.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	688.58x	N/A
Forward P/S (NTM)	1.51x	21.85x
Revenue & Growth
Revenue (TTM)	$451M	$29M
Revenue Growth (YoY)	16.8%	-83.9%
Forward Rev Growth	27.5%	-58.1%
Profitability
Gross Margin (TTM)	94.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-7.1%	-604.8%
Net Margin (TTM)	-12.4%	-560.9%
FCF Margin (TTM)	-4.0%	-111.7%
Net Income (TTM)	$-56M	$-161M
FCF (TTM)	$-18M	$-32M
EPS (TTM)	-$0.22	-$1.59
ROE (TTM)	-3600.0%	-4331.0%
ROA (TTM)	-1077.0%	-2759.0%
ROIC (TTM)	-1506.0%	-4331.0%
Financial Health
Cash	$97M	$90M
Debt	$252M	$0
Net Cash/Debt	$-155M	$90M
Current Ratio (TTM)	3.34x	10.58x
Quick Ratio (TTM)	2.89x	10.49x
Debt/Equity (TTM)	1.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	1.34
52W Performance	-35.2%	33.6%
YTD Performance	-46.7%	-32.7%
% from 52W High	-61.0%	-60.0%
% from 52W Low	3.1%	34.7%
Efficiency & Yields
Asset Turnover (TTM)	0.87x	0.05x
FCF Yield (TTM)	-2.2%	-3.7%
Earnings Yield (TTM)	-6.9%	-18.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	12.8	-195.5
EV/GP/RG	0.10	N/A
Ticker research	View ARDX research	View GLUE research

Valuation

P/S Ratio

ARDX

1.80x

GLUE

30.29x

EV/FCF

ARDX

-53.85x

GLUE

-24.32x

Growth & revenue

Revenue Growth TTM

ARDX

16.8%

GLUE

-83.9%

Forward Revenue Growth

ARDX

27.5%

GLUE

-58.1%

Profitability & performance

Gross Margin

ARDX

94.4%

GLUE

0.0%

ROE

ARDX

-3600.0%

GLUE

-4331.0%

FCF Yield %

ARDX

-2.2%

GLUE

-3.7%

52-Week Performance

GLUE

33.6%

ARDX

-35.2%

Detailed metrics comparison

ARDX

Ardelyx Inc

GLUE

Monte Rosa Therapeutics Inc

Market Cap

ARDX$810M

GLUE$870M

Enterprise Value

ARDX$965M

GLUE$780M

Price

ARDX$3.28

GLUE$10.30

P/E Ratio

ARDXN/A

GLUEN/A

P/S Ratio

ARDX1.80x

GLUE30.29x

EV/Sales

ARDX2.14x

GLUE27.15x

EV/EBITDA

ARDX454.80x

GLUE47.84x

P/B Ratio

ARDX5.59x

GLUE1.84x

P/FCF Ratio

ARDXN/A

GLUEN/A

EV/FCF

ARDX-53.85x

GLUE-24.32x

PEG Ratio

ARDXN/A

GLUEN/A

Forward P/E (NTM)

ARDX688.58x

GLUEN/A

Forward P/S (NTM)

ARDX1.51x

GLUE21.85x

Revenue (TTM)

ARDX$451M

GLUE$29M

Revenue Growth (YoY)

ARDX16.8%

GLUE-83.9%

Forward Rev Growth

ARDX27.5%

GLUE-58.1%

Gross Margin (TTM)

ARDX94.4%

GLUE0.0%

Operating Margin (TTM)

ARDX0.0%

GLUE0.0%

EBITDA Margin (TTM)

ARDX-7.1%

GLUE-604.8%

Net Margin (TTM)

ARDX-12.4%

GLUE-560.9%

FCF Margin (TTM)

ARDX-4.0%

GLUE-111.7%

Net Income (TTM)

ARDX$-56M

GLUE$-161M

FCF (TTM)

ARDX$-18M

GLUE$-32M

EPS (TTM)

ARDX-$0.22

GLUE-$1.59

ROE (TTM)

ARDX-3600.0%

GLUE-4331.0%

ROA (TTM)

ARDX-1077.0%

GLUE-2759.0%

ROIC (TTM)

ARDX-1506.0%

GLUE-4331.0%

Cash

ARDX$97M

GLUE$90M

Debt

ARDX$252M

GLUE$0

Net Cash/Debt

ARDX$-155M

GLUE$90M

Current Ratio (TTM)

ARDX3.34x

GLUE10.58x

Quick Ratio (TTM)

ARDX2.89x

GLUE10.49x

Debt/Equity (TTM)

ARDX1.69x

GLUE0.00x

Debt/Assets (TTM)

ARDX0.0%

GLUE0.0%

Interest Coverage (TTM)

ARDXN/A

GLUEN/A

Net Debt/EBITDA (TTM)

ARDX0.00x

GLUE0.00x

Beta

ARDX0.72

GLUE1.34

52W Performance

ARDX-35.2%

GLUE33.6%

YTD Performance

ARDX-46.7%

GLUE-32.7%

% from 52W High

ARDX-61.0%

GLUE-60.0%

% from 52W Low

ARDX3.1%

GLUE34.7%

Asset Turnover (TTM)

ARDX0.87x

GLUE0.05x

FCF Yield (TTM)

ARDX-2.2%

GLUE-3.7%

Earnings Yield (TTM)

ARDX-6.9%

GLUE-18.5%

Dividend Yield (TTM)

ARDXN/A

GLUEN/A

Rule of 40

ARDX12.8

GLUE-195.5

EV/GP/RG

ARDX0.10

GLUEN/A

Ticker research

View ARDX research View GLUE research

Metric	ARDX Ardelyx Inc	GLUE Monte Rosa Therapeutics Inc
Market & Valuation
Market Cap	$810M	$870M
Enterprise Value	$965M	$780M
Price	$3.28	$10.30
P/E Ratio	N/A	N/A
P/S Ratio	1.80x	30.29x
EV/Sales	2.14x	27.15x
EV/EBITDA	454.80x	47.84x
P/B Ratio	5.59x	1.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-53.85x	-24.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	688.58x	N/A
Forward P/S (NTM)	1.51x	21.85x
Revenue & Growth
Revenue (TTM)	$451M	$29M
Revenue Growth (YoY)	16.8%	-83.9%
Forward Rev Growth	27.5%	-58.1%
Profitability
Gross Margin (TTM)	94.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-7.1%	-604.8%
Net Margin (TTM)	-12.4%	-560.9%
FCF Margin (TTM)	-4.0%	-111.7%
Net Income (TTM)	$-56M	$-161M
FCF (TTM)	$-18M	$-32M
EPS (TTM)	-$0.22	-$1.59
ROE (TTM)	-3600.0%	-4331.0%
ROA (TTM)	-1077.0%	-2759.0%
ROIC (TTM)	-1506.0%	-4331.0%
Financial Health
Cash	$97M	$90M
Debt	$252M	$0
Net Cash/Debt	$-155M	$90M
Current Ratio (TTM)	3.34x	10.58x
Quick Ratio (TTM)	2.89x	10.49x
Debt/Equity (TTM)	1.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	1.34
52W Performance	-35.2%	33.6%
YTD Performance	-46.7%	-32.7%
% from 52W High	-61.0%	-60.0%
% from 52W Low	3.1%	34.7%
Efficiency & Yields
Asset Turnover (TTM)	0.87x	0.05x
FCF Yield (TTM)	-2.2%	-3.7%
Earnings Yield (TTM)	-6.9%	-18.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	12.8	-195.5
EV/GP/RG	0.10	N/A
Ticker research	View ARDX research	View GLUE research